San Diego-based biopharmaceutical company, Neurocrine Biosciences, Inc. has developed and introduced an array of treatment options for neurological, endocrine, and psychiatric disorders. Among its portfolio of products are INGREZZA and DYSVAL, both treatments for tardive dyskinesia, and ONGENTYS, useful as a supplementary therapy for levodopa/DOPA decarboxylase inhibitors in Parkinson's disease patients. The company's product pipeline includes NBI-921352, a pediatric and adult focal epilepsy treatment, and NBI-827104, designed to treat rare pediatric epilepsy and essential tremor. The company collaborates with several major pharmaceutical companies, including AbbVie, Takeda Pharmaceutical, and Voyager Therapeutics.
Neurocrine Biosciences's ticker is NBIX
The company's shares trade on the NASDAQ stock exchange
They are based in San Diego, California
There are 501-1000 employees working at Neurocrine Biosciences
It is neurocrine.com
Neurocrine Biosciences is in the Healthcare sector
Neurocrine Biosciences is in the Biotechnology industry
The following five companies are Neurocrine Biosciences's industry peers: